SIA
ABBV icon

Strategic Investment Advisors’s AbbVie ABBV Stock Holding History

Strategic Investment Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.06M Buy
14,077
+7,271
+107% +$1.61M 0.21% 60
2025
Q4 		$1.56M Buy
6,806
+16
+0.2% +$3.65K 0.13% 75
2025
Q3 		$1.57M Sell
6,790
-341
-5% -$69.4K 0.14% 75
2025
Q2 		$1.32M Sell
7,131
-2,704
-27% -$503K 0.13% 81
2025
Q1 		$2.06M Sell
9,835
-359
-4% -$69.8K 0.22% 62
2024
Q4 		$1.81M Buy
10,194
+32
+0.3% +$5.88K 0.19% 71
2024
Q3 		$2.01M Sell
10,162
-31
-0.3% -$5.79K 0.22% 67
2024
Q2 		$1.75M Sell
10,193
-24
-0.2% -$3.98K 0.21% 68
2024
Q1 		$1.86M Buy
10,217
+45
+0.4% +$7.75K 0.24% 61
2023
Q4 		$1.58M Sell
10,172
-638
-6% -$93K 0.23% 66
2023
Q3 		$1.61M Buy
10,810
+43
+0.4% +$6.31K 0.27% 55
2023
Q2 		$1.45M Buy
10,767
+91
+0.9% +$13.3K 0.2% 50
2023
Q1 		$1.7M Sell
10,676
-606
-5% -$92.6K 0.31% 53
2022
Q4 		$1.82M Sell
11,282
-4
-0% -$613 0.38% 47
2022
Q3 		$1.51M Buy
11,286
+172
+2% +$24.7K 0.34% 53
2022
Q2 		$1.7M Sell
11,114
-31
-0.3% -$4.74K 0.34% 50
2022
Q1 		$1.81M Sell
11,145
-2,802
-20% -$407K 0.34% 52
2021
Q4 		$1.89M Buy
13,947
+569
+4% +$67.2K 0.36% 52
2021
Q3 		$1.44M Buy
13,378
+1,783
+15% +$204K 0.32% 63
2021
Q2 		$1.31M Buy
11,595
+3,248
+39% +$366K 0.3% 69
2021
Q1 		$903K Buy
8,347
+1,215
+17% +$130K 0.23% 88
2020
Q4 		$764K Sell
7,132
-2,337
-25% -$225K 0.22% 91
2020
Q3 		$828K Sell
9,469
-1,174
-11% -$111K 0.28% 68
2020
Q2 		$1.04M Buy
10,643
+673
+7% +$59.3K 0.39% 55
2020
Q1 		$760K Buy
9,970
+435
+5% +$37.1K 0.35% 61
2019
Q4 		$844K Buy
9,535
+314
+3% +$26.1K 0.35% 61
2019
Q3 		$698K Buy
9,221
+1,167
+14% +$80K 0.33% 58
2019
Q2 		$586K Buy
8,054
+2,222
+38% +$175K 0.32% 59
2019
Q1 		$470K Buy
5,832
+933
+19% +$76.3K 0.32% 62
2018
Q4 		$452K Buy
+4,899
New +$431K 0.41% 56

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Strategic Investment Advisors's ABBV Position: Q1 2026 in Review

Strategic Investment Advisors increased its AbbVie (ABBV) stake by 107% in Q1 2026, buying an estimated $1.61M and bringing the position to 14,077 shares worth $3.06M. The position accounts for 0.21% of the portfolio, ranked #60.

Strategic Investment Advisors first reported a position in ABBV in Q4 2018 and has held it in 30 quarters since. 4,081 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Strategic Investment Advisors held 14,077 shares of AbbVie worth $3.06M as of Q1 2026.
  • Strategic Investment Advisors bought 7,271 AbbVie shares in Q1 2026, an estimated $1.61M.
  • AbbVie made up 0.21% of Strategic Investment Advisors's portfolio in Q1 2026, its #60 holding.
  • Strategic Investment Advisors first reported a position in AbbVie in Q4 2018 and has held it in 30 quarters since.
  • 4,081 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Strategic Investment Advisors's 13F filing for Q1 2026, filed 18 May 2026.